Protecting transplant patients from severe viral diseases

MISSION

 

  • SpikImm is a Paris-based, clinical-stage biotech founded in 2021 by Truffle Capital in partnership with Institut Pasteur that develops monoclonal antibodies (mAbs) for the prevention of severe viral infections in transplant patients. 

  • Transplant patients, who receive immunosuppressive therapy to prevent rejection, are very vulnerable to viral infections and often respond poorly to vaccines.

  • When exposed to viruses such as SARS-CoV-2 and BK Virus (BKV), kidney transplant patients and hematopoietic stem cell transplant patients are at high risk of developing severe forms and complications of these infections.

  • To address this major unmet need, SpikImm, is currently developing a unique portfolio of long-acting human mAbs targeting different viruses. These mAbs will provide a broad, immediate and long-lasting protection for transplant patients, improving transplant outcomes, patients’ prognosis and quality of life.

TEAM

MANAGEMENT

Dr. James (Jim) Philllips

Dr. James (Jim) Philllips

CEO

Dr. Catherine Combot-Plétan

Dr. Catherine Combot-Plétan

Chief Development Officer

Pr. Karine Lacombe

Pr. Karine Lacombe

Chief Medical Officer

Vincent Dagommer

Vincent Dagommer

Chief Financial Officer

Dr. Jérôme Tiollier

Dr. Jérôme Tiollier

CMC expert

INVENTOR & CHIEF SCIENTIFIC OFFICER

Dr. Hugo Mouquet

Dr. Hugo Mouquet

BOARD OF DIRECTORS

Dr. Philippe Pouletty

Dr. Philippe Pouletty

Chairman

Pr. Jorge Kalil

Pr. Jorge Kalil

Pr. Hartmut J. Ehrlich

Pr. Hartmut J. Ehrlich

Antoine Pau, PharmD

Antoine Pau, PharmD

SCIENCE

Potent human broadly SARS-CoV-2–neutralizing IgA and IgG antibodies effective against Omicron BA.1 and BA.2

MEDIA

Press release 2024/04/16 preview

Press release 04/16/2024 - HuMABK

SpikImm awarded by France 2030

Preview of Washington Post article by Mark Johnson on Novembre 21, 2022

Washington Post, Novembre 2022

Pasteur.fr

PR April 2022

Press release April 2022

france 2030

Press release France 2030

Nature.com

Businesswire.com